Latest News
Cure SMA Releases Status Update on Data Accuracy Issues with Zolgensma
Yesterday, the FDA issued a statement identifying data accuracy issues with Avexis’ SMA therapy, Zolgensma. Cure SMA is in communication with the FDA and is committed to representing the SMA patient voice […]
Read More ›FDA Issues Statement on Data Accuracy Issues with Recently Approved Gene Therapy
Today, the FDA issued the below statement identifying data accuracy issues with AveXis’ SMA therapy, Zolgensma. Cure SMA is investigating this issue and will report when we have further details. We will be […]
Read More ›Biogen Issues Community Statement on Spinraza
Biogen has provided the following community statement on Spinraza. Dear members of the SMA community, Following a busy spring of data presentations at medical congresses and the annual Cure SMA […]
Read More ›SMA Awareness Month 2019 Has Begun!
SMA Awareness Month occurs in August! The SMA community officially recognizes August as Spinal Muscular Atrophy Awareness Month and Cure SMA has been coordinating activities since 1996. August is a […]
Read More ›Biogen Announces New NURTURE Data at the 2019 Annual SMA Conference
Biogen today announced new results from the NURTURE study, adding data to the longest study of spinal muscular atrophy (SMA) in pre-symptomatic infants (n=25). These data reported, after up to […]
Read More ›Updated SMA Drug Pipeline Now Available
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 23 active programs, including two approved therapies. 15 pharmaceutical partners. 6 programs in clinical trials. An […]
Read More ›